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Drug resistanceFOXM1 is a transcription factor required for a wide spectrum of essential biological functions, including DNA
damage repair, cell proliferation, cell cycle progression, cell renewal, cell differentiation and tissue homeostasis.
Recent evidence suggests that FOXM1 also has a role inmany aspects of the DNA damage response. Accordingly,
FOXM1 drives the transcription of genes for DNA damage sensors, mediators, signal transducers and effectors. As
a result of these functions, it plays an integral part inmaintaining the integrity of the genome and so is key to the
propagation of accurate genetic information to the next generation. Preserving the genetic code is a vitalmeans of
suppressing cancer and other genetic diseases. Conversely, FOXM1 is also a potent oncogenic factor that is essen-
tial for cancer initiation, progression and drug resistance. An enhanced FOXM1 DNA damage repair gene expres-
sion network can confer resistance to genotoxic agents. Developing a thorough understanding of the regulation
and function of FOXM1 in DNA damage response will improve the diagnosis and treatment of diseases including
cancer, neurodegenerative conditions and immunodeﬁciency disorders. It will also beneﬁt cancer patients with
acquired genotoxic agent resistance.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. FOXM1
Forkhead Box M1 (FOXM1), also known as HNF-3, HFH-11, MPP2,
Win, and Trident, is a member the Forkhead superfamily of transcrip-
tion factors [1,2]. The FOXM1 protein consists of 3 functional regions,
an N-terminal Repressor Domain (NRD), a Forkhead/Winged-helix
domain (FKH) and a Transcativation Domain (TAD). The NRD is found
within theN-terminus and the TAD,which has transactivational activity,
is located in the C-terminal. The NRD and TAD are separated by a highly
conserved Forkhead DNA-binding domain (FHD). It is believed that the
NRD folds back to suppress the transactivational activity of the TAD.
The human FOXM1 gene consists of 10 exons. Exons Va and VIIa can
be alternatively spliced, to give rise to three common isoforms, FOXM1a,
FOXM1b and FOXM1c [1,2]. FOXM1a lacks transactivation activity
because of the presence of both extra exons, Va and VIIa, within its
transactivation domain. Both FOXM1b (which lacks either exons) and
FOXM1c (contains Va only) are transcriptionally active [1,2]. It has
been suggested that FOXM1b is present in the predominant species of
cancer cells and has a greater transforming potential compared with
FOXM1c [3].and Cancer, Imperial College
d, London W12 0NN, UK. Tel.:
.
. This is an open access article underFOXM1 has a vital role in embryonic development, adult tissue
homeostasis, cancer initiation and progression [4]. It regulates a broad
spectrum of normal essential biological functions, including DNA
damage repair, cell proliferation, cell cycle progression, cell renewal,
cell differentiation, cell migration, angiogenesis and cell survival.
The expression of FOXM1 is frequently upregulated in many malig-
nancies, including cancers of the liver, prostate, brain, breast, lung,
colon, pancreas, skin, cervix, ovary, mouth, blood and nervous system
[5–17]. Upregulation of FOXM1 expression is an early event during can-
cer development [13]. Accordingly, genome-wide proﬁling studies of
gene expression in cancers have independently conﬁrmed that FOXM1
is one of themost frequently upregulated genes in humanmalignancies
[18,19]. These ﬁndings suggest that FOXM1 has a key role in cancer
initiation. Furthermore, FOXM1 also promotes cancer progression by fa-
cilitating cancer angiogenesis, invasion and metastasis [10,20]. Recent
evidence also implicates FOXM1 deregulation in the development of
cancer genotoxic therapeutic agent resistance.
2. DNA damage and response
The genetic information of a cell is stored and encoded within its
DNA, the basic building blocks of genes. During the lifespan of a eukary-
otic cell, its DNA is subject to a continuous range of assaults derived
from its external and cellular environment. These assaults culminate
in a wide variety of DNA lesions, including nucleotide modiﬁcations
and DNA breaks [21].the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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include ultraviolet (UV) light, ionizing radiation, toxins and genotoxic
therapeutic agents. By-products of normal cellular metabolism, such
as reactive oxygen species (ROS) from oxidative respiration and lipid
peroxidation are amongst some of the cellular derived agents that
cause DNA damage. Additionally errors made during DNA replication
can also cause DNA damage. The genotoxic agents target DNA and
form adducts that cause DNA lesions such as base loss, DNA single-
strand breaks (SSBs) or prevent DNA replication and transcription
[21]. Most of these DNA lesions will ultimately culminate in DNA
double-strand breaks (DSBs), the most toxic and difﬁcult DNA lesion
to repair in cells [21].
In response to DNA damage, eukaryotic cells trigger a surveillance
and reaction mechanism called DNA damage response (DDR) [21].
DDRmonitors chromatin integrity, to detect and signal for the presence
of DNA damage and to coordinate DNA repair with cell-cycle arrest and
cell termination. Upon detection of damage, DNA damage checkpoints
are activated to initiate temporary cell cycle arrest/delay [21]. Cell
cycle arrest permits extra time for repair of the damaged DNA. If DNA
damage is irreparable or cannot be repaired in time, DNA damage
checkpoints induce cell death or senescence, a state of permanent cell
cycle arrest [21,22]. Conversely, if the cell cycle checkpoints are bypassed,
incorrect bases are incorporated into DNA during replication which can
have adverse effects [21]. This can result in heritable mutations, which
can ultimately bring about cancer and other genetic disorders. As a result,
through the DDR, organisms are able tomaintain integrity of the genome
and prevent faulty genetic information passing on to subsequent gener-
ations of cells. Therefore, the DDR is essential for the suppression of
cancer and the propagation of correct genetic information from one
generation to the next.
In cancer, treatment modalities commonly comprising radiation
therapy or DNA-damaging drugs, such as platinum compounds, anthra-
cyclines, topoisomerase inhibitors and alkylation agents, are the main-
stay of cancer treatment in the clinic [23–27]. These genotoxic agents
are also used before surgery in neoadjuvant therapy to shrink the tu-
mour before operation and after surgery as adjuvant therapy to prevent
cancer relapse. The objective of genotoxic therapy is to induce irrepara-
ble genetic damages preferentially in the fast growing cancer cells, so
that they will undergo cell death or permanent cell cycle arrest through
DDR signalling, thus blocking their ability to divide and to proliferate
further [28]. However, the long-term efﬁcacy ofmost of these genotoxic
agents is often hindered by the eventual development of resistance,
which is a major cause of cancer treatment failure [29]. Recent research
has revealed that FOXM1 plays a key role in DNA damaging agent resis-
tance and if aberrantly activated or expressedmay promote the develop-
ment of drug resistance [30,31]. This review will discuss the emerging
insights into the role of FOXM1 in the DDR, in particular evaluating its
implications on cancer initiation and genotoxic agent resistance.
3. Modulation of the DNA damage response by FOXM1 in DNA
damage repair
The central role of FOXM1 in DNA repair is underscored by the ob-
servation that increased DNA breaks are found in FOXM1-deﬁcient
cells [32]. Recent research has provided further insights into the impor-
tance of FOXM1 in the DDR. This has been shown through the use of
gene expression array screens and candidate gene approaches. The
ability of FOXM1 to induce DNA repair involves transcriptional control
of a network of DNA damage sensing, mediating, signalling and repair
genes [32–36].
In eukaryotic cells, the wide spectrum of exogenous and endoge-
nous genotoxic agents can trigger a wide variety of DNA lesions. These
lesions are managed by a broad range of DNA damage repair pathways,
including nucleotide excision repair (NER), base excision repair (BER),
fanconi anaemia (FA)/BRCA pathway, mismatch repair (MMR), homol-
ogous recombination (HR), non-homologous end-joining (NHEJ), andmicrohomology-mediated end joining (MMEJ) [21]. Double strand
breaks (DSBs) are the most harmful types of DNA lesions and are pre-
dominantly repaired by HR and NHEJ [21,37]. MMEJ or Alternative
end-joining (A-EJ) is a less-well-deﬁned Ku-independent NHEJ repair
pathway. It can proceed in the absence of key NHEJ factors and is highly
mutagenic, often causing deletionmutations [38]. Both NHEJ andMMEJ
can operate in any phase of the cell cycle but are error-prone, while HR
is generally restricted to S and G2 phases. This is due to the fact that HR
using sister chromatid sequences as templates to mediate accurate
repair.
FOXM1 regulates the transcription of a multitude of genes essential
for DNA damage response. NER functions to remove and replace bulky
helix-distorting base lesions, such as pyrimidine dimers [21,39,40].
The correct DNA structure is restored through gap-ﬁlling and religation
by replication factor C (RFC), proliferating cell nuclear antigen (PCNA),
DNA polymerase (DNA pol) δ or ε, DNA ligase I and replication protein
A (RPA). Out of these proteins FOXM1 transcriptionally activates the ex-
pression of DNA pol, PolE2 and RFC4, a subunit of RFC which functions
cooperatively with PCNA [41]. The PolE gene encodes DNA pol ε, and
mutations in this gene have recently been identiﬁed to be associated
with familial adenomas and colorectal cancer (CRC) [42]. BER repairs
damage to single bases caused by oxidation, alkylation, hydrolysis, or
deamination throughout the cell cycle (Figs. 1 and 2) [21,43,44]. The
repair is completed by nucleases (AP endonuclease), end processing en-
zymes (polynucleotide kinase—phosphatase), polymerases (pol β and
Pol λ for short-patch BER, and pol δ and pol ε for long-patch BER) and
ligases (DNA ligase III along with its cofactor XRCC1 for short-patch
BER, and DNA ligase III for long-patch BER). FOXM1 is a cofactor for
DNA ligase III, involved in short-patch BER [32]. In addition FOXM1 is
a transcriptional regulator of the base excision repair factor X-ray
cross-complementing group 1 (XRCC1) [32]. The (FA)/BRCA pathway
is primarily activated by ionizing radiation, inducing inter-strand DNA
crosslinks [21,45]. The (FA)/BRCA and NER repair pathways share com-
mon components, and often work together to repair single strand DNA
(ssDNA) damage. FOXM1 also contributes to a number of single strand
break SSB repairmechanisms by transcriptionally activating the expres-
sion of genes, such as RFC4, Exo1 and PolE2 [41]. RFC4 is a subunit of RFC,
which functions cooperativelywith PCNAandDNApol. The co-operating
RFC4, PCNA and DNA polymerases direct ssDNA to ﬁll the gap left fol-
lowing the removal of the segment containing the mismatched base
during MMR [46].
HR is a relatively error-free DSB DNA repair mechanism that uses a
long homologous sequence (the undamaged sister chromatid or the ho-
mologous chromosome) to guide repair [47] (Figs. 1 and 2). In HR, DDR
is initiated through the detection of DSBs by theMRN (MRE11–RAD50–
NBS1) complex (Fig. 2). There is evidence to suggest that FOXM1 indi-
rectly enhances the stability of MRN subunits, including MRE11 and
RAD50, by upregulating NBS1 (Nijmegen breakage syndrome protein
1) expression at the transcriptional level [48]. Through enhanced stabil-
ity of these MRN subunits, further DNA damage repair response is pro-
moted [48]. The MRN complex helps to recruit and activate key DDR
signalling kinases, including ATM at the sites of DNA damage. In turn,
ATM phosphorylates H2AX, its downstream target histone, ultimately
leading to the recruitment of DNA repair proteins to the damage sites
[49]. In addition, the ATM kinase also directly phosphorylates modula-
tor proteins, including p53BP1 (p53-binding protein 1), SMC1, BRCA1,
NBS1 and CHK2. Such proteins are essential for triggering cell-cycle ar-
rest, and DNA repair [50–53], and FOXM1 has been implicated in their
signalling network at different levels and in many ways [32,48,50–55].
Following the detection of DNA damage, HR repair begins with
nucleolytic resection of broken DNA ends facilitated by the CtBP-
interacting protein (CtIP). Next, the breast cancer susceptibility gene
products 1 (BRCA1), BRCA2 and several RAD51-related proteins (eg.
XRCC2, XRCC3, RAD51B, RAD51C, RAD51D and DMC1), promote the
displacement of RPA by the strand exchange protein RAD51, resulting
in the formation of a RAD51 nucleoprotein ﬁlament [21]. FOXM1 has
Fig. 1. FOXM1 regulates essential mediators of DNA damage recognition and excision of damaged DNA. Schematic diagramme depicting the effect of FOXM1 binding to the Forkhead
response element region (FHRE) of NBS1, Csk1, Skp2 (genes crucial for DNA damage recognition) and EXO1, XRCC1, Polβ/ɛ (excision of damaged DNA genes). All FOXM1 transcriptional
targets are high-lighted in green. Clock-wise from top left corner: FOXM1 transcription of NBS1 is important for the formation of the MRN complex (NBS1, RAD50, MRE11). This partic-
ipates in the recognition of double strandedDNA breaks in both homologous and non-homologous end-joining DNA damage repair processes; FOXM1 also regulates Csk1 and Skp2: these
formpart of the Skp2–Csk1 complexwhich, upon detection of double-stranded DNA damage, are phosphorylated and subsequently poly-ubiquitinated by K63, thus initiating subsequent
steps in NHEJ repair; FOXM1 regulation of Polβ/ɛ permits excision of erroneous DNA sequence upon mismatch repair, when in the presence of FEN1 and PCNA; FOXM1 control of XRCC1
allows excision of the incorrect base pairwhen coupledwith Polβ, in the long-patchbase-excision repair process; FOXM1 regulates EXO1,which is key for both homologous recombination
and short-patch base excision repair pathways: in combination with the MRN complex, RPA and BLM, it allows for the resection of the damaged strands.
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[32]. BRCA2 is an important HR regulator which binds the ssDNA and
directly interactswith the recombinase RAD51 to stimulate strand inva-
sion during HR. RAD51 then searches for homologous sequences and
catalyzes an exchange strand between the broken duplex and the intact
sister chromatid. RAD51 itself is a direct transcriptional target of FOXM1.
Induction of RAD51 by FOXM1 in glioblastomas has been shown to
confer resistance to the genotoxic alkylating agent temozolomide [32].
FOXM1 directly regulates the transcription of BRCA1-interacting
protein-terminal helicase 1 (BRIP1/BACH1/FRACJ) [34,56]. BRIP1 binds
to and functions cooperatively with BRCA1 to promote HR repair. The
BRCA1-bound BRIP1 unwinds damaged dsDNA to allow other repairproteins to access and process the damaged DNA [34,56]. The FOXM1
target BRIP1 is important in HR. This is reﬂected by the fact that individ-
uals with both copies of the BRIP1 genemutated are predisposed to the
FA type J (FA-J) genetic disorder. These individuals are also prone to
developing leukaemias and cancers of the head, neck, breast, stomach,
ovary, cervix and skin [56–59]. These BRIP1 mutations severely reduce
BRIP1 activity, resulting in DNA breaks that have not properly been
repaired and genetic damage accumulating over time. Beyond HR,
BRIP1 also contributes to processing interstrand crosslinks (ICLs) during
MMR [21,46]. This is mediated, in a BRCA1 independent manner,
through its interaction with the MutLα mismatch repair complex,
consisting of theMLH1 and PMS2 heterodimer [60,61]. Uponmismatch
Fig. 2. FOXM1 controls proteins that participate in the unwinding of the damaged DNA, chromatin remodelling and DNA synthesis and ligation steps of the DNA damage response path-
ways. Schematic diagram representing FOXM1 transcriptional control of BRIP1, NBS1, SIRT1, XRCC1, RFC4 and Polδ/ɛ and their effect on chromatin remodelling, DNA synthesis, ligation and
damage unwinding. FOXM1 controls its transcriptional targets by binding to the Forkhead response elements present in their promoter regions. The targets can be distinguished by their
green colour. Clock-wise from top left corner: FOXM1 transcriptional regulation of BRIP1 leads to the unwinding of the damaged DNA during homologous recombination. This step entails
DNA damage recognition by theMRN complex and phosphorylatedATM, aswell as the formation of the Ctlp, BRCA1, BRIP1 complex; FOXM1 controls both SIRT1 and NBS1, both critical in
the chromatin remodelling prior to the initiation of the DNA damage response pathways. Upon DNA damage, SIRT1 deacetylates NBS1. NBS1 induces ATM phosphorylation, and, in turn,
ATM phosphorylates KAP1, leading to its loss of SUMOylation. Subsequently CHD3, NuRD and SETDB1 are also released, allowing chromatin relaxation; FOXM1 positively regulates RFC4
and Polδ/ɛ: both participate inDNA synthesis and ligation stepswith PCNA andRFC duringmismatch repair; FOXM1also controls transcription ofXRCC1,which functions inDNA synthesis
and ligations steps of both short-patch base-excision repair and non-homologous end-joining repair processes. To perform its action, it couples with LNG3 or DNA Ligase III respectively.
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remove the segment containing the mismatched base, and Exo1 is
again another FOXM1 direct target [41].
FOXM1 can further potentially enhanceHR repair indirectly through
promoting the transcription of S-phase kinase-associated protein 2
(Skp2) and cyclin-dependent kinases regulatory subunit 1 (Cks1) [62].
Skp2 and Cks1 are key components of the Skp2–SCF E3 ligase complex
that mediates the K63-linked ubiquitination of NBS1. This process is
crucial for the interaction of NBS1 with ATM, thereby the activation of
ATM and its recruitment to the DNA damage foci to initiate HR repair[63]. Skp2 deﬁcient cells consistently exhibit HR repair defects and
ionizing irradiation sensitivity [63]. The MRN complex is also involved
in NHEJ repair (Fig. 1), particularly in response to etoposide-induced
DSBs [64]. Cells deﬁcient in MRE11 or NBS1, but not ATM, exhibit a
major NHEJ repair defect, suggesting that the function of the MRN in
NHEJ repair is independent of ATM [64].
Collectively, these ﬁndings provide strong indications that FOXM1
plays an integral part in DNA damage response, driving the transcrip-
tion of genes encoding for DNAdamage sensors,mediators, signal trans-
ducers and effectors.
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DNA repair
Chromatin is the complex formed by genomicDNA and its associated
proteins. The local chromatin structure controls the efﬁciency of DNA
repair, through governing the access of DNA damage response proteins
to sites of DNA damage. An example of how the chromatin structure
controls DNA repair efﬁciency is the modulation of DDR by heterochro-
matin. Heterochromatin is a highly compacted chromatin that is be-
lieved to constitute an obstacle for DNA repair. The processing and
repair of DSBs located within heterochromatin is much slower than
those in less dense euchromatin [65]. Concordantly, DNA damage foci
are formed preferentially in euchromatin compared to heterochromatin
after exposure to genotoxic agents [65].
Through transcriptional control, FOXM1 directly and indirectly con-
trols many chromatin structure-modifying genes, and thereby, plays a
role in chromatin structure remodelling and DNA repair. One example
in which FOXM1 directly controls chromatin structure includes its tran-
scriptional activation of the class III histone deacetylase SIRT1. SIRT1
functions to deacetylate NBS1, thereby enabling it to be phosphorylated
and so capable of activating ATM signalling [66]. At the same time,
FOXM1 can promote chromatin accessibility via KAP-1 through directly
promoting NBS1 expression [48] as well as enhancing its activity
through inducing SIRT1 expression [66]. FOXM1 also directly regulates
the transcription of the polycombprotein Bmi-1 [58], which is recruited
to the sites of DNA damage and required for DNA damage-induced
ubiquitination of histone H2A [67].
FOXM1 can be seen in indirect control of chromatin structuremodify-
ing genes in FOXM1-induced NBS1 activation of ATM [48]. This can indi-
rectly facilitate the access of repair proteins at sites of DNA lesions
(Fig. 2). Such ATM activation enhances DNA damage repair via (KAP-1),
also known as Tripartite motif-containing 28 (TRIM28) and tran-
scriptional intermediary factor 1β (TIF1β) [65], as ATM-mediated phos-
phorylation of KAP-1 can trigger chromatin relaxation at sites of DSBs
[65,68,69]. FOXM1 has also been shown to regulate the expression
of DNA methyltransferase DNMT1. Through DNMT1, FOXM1 plays an
indirect role in chromatin remodelling at sites of DNA damage. It does
this through the chromatin remodelling factor HELLS, a SNF2 (sucrose
non-fermenter)-like helicase involved in promoting DNA methylation
in mammalian cells [70]. Intriguingly, DNMT1 has a role in promoting
DNA damage repair through decondensing chromatin at sites of DNA
damage; this is independent of its methyltransferase activity [70]. It is
believed that the DNMT1 DNA damage response involves a currently
unknown mechanism that requires further investigation.
It is evident that FOXM1 is pertinent to DNA damage repair in ways
other than just regulating the expression of crucial DNA damage sensor
and repair genes. Together, these ﬁndings indicate that one suchmeans
is through promoting the expression of gene products that can modu-
late local chromatin structure at the damage sites to enhance DNA
damage repair.
5. DNA damage checkpoints and FOXM1
Apart from DNA repair, the DNA damage response also impacts cell
cycle progression, cell survival, cell senescence and the cellular tran-
scription programme [71]. When damage to DNA is detected, surveil-
lance mechanisms called ‘DNA damage checkpoints’ are activated to
stall cell cycle progression, allowing extra time for DNA repair to take
place. FOXM1 is an integral component of the DNA damage checkpoint
signalling network. It drives the transcription of a diverse range of genes
encoding for DNA damage sensors, signalling mediators and effectors
for cell cycle checkpoints, cell death and senescence. The ATM/Ataxia
telangiectasia and RAD3 related (ATR) and their downstream Chk1/2
kinases are key components of the cell cycle checkpoint signal transduc-
tion network. For DSBs, theDNA damage is usually detected by theMRN
complex, which helps to recruit and activate ATM. ATM phosphorylatesand activates downstream effectors, including p53, Chk1/2, BRCA1, to
induce cell cycle arrest, transcription activation, apoptosis and senes-
cence. In ssDNA break response, the ssDNA bound RPA complex recruits
and activates the ATM–ATR protein, RAD17 and the 911 (RAD9–RAD1–
Hus1) complex [72]. The activatedATR thenphosphorylates bothRAD17
and 911 to initiate downstream signalling required for the DNA-
damage-induced cell cycle checkpoints.
Besides promoting the expression of DNA damage sensor andmedi-
ator proteins, FOXM1 also integrates the DNA damage response signals
with the cell cycle machinery to engage in cell cycle checkpoints. Ac-
cordingly, the expression and transcriptional activity of FOXM1 is
substantially downregulated in response to genotoxic stress through
transcriptional and post-translational mechanisms. Upon genotoxic
drug treatment, ATMand p53 coordinately regulate FOXM1 expression.
This expression is through the E2F1 transcription factor in breast cancer
cells, with ATM activating and p53 repressing FOXM1 transcription
through a common E2F-site on its promoter [36,73]. In consequence,
DNA damage will result in an initial induction of FOXM1 expression
followed by an eventual downregulation. This occurs as p53 appears
to be dominant over ATM in the regulation of FOXM1 expression. How-
ever, in the absence of functional p53, genotoxic stress will lead to an
induction of FOXM1 expression through ATM and E2F1. Furthermore,
the genotoxic agent epirubicin has been shown to induce FOXM1 tran-
scription via E2F1 activating the p38MAPK–MK2 signalling axis [73,74].
Beyond transcriptional control, the activity of FOXM1 is also ﬁne-tuned
by post-translational modiﬁcations. Previous studies have shown that
treatment with DNA-damaging agents, such as γ-irradiation, etoposide
and UV, promotes CHK2-induced phosphorylation of FOXM1. Such
phosphorylation of FOXM1 results in the stabilization of the protein
leading to the transcriptional activation of downstream DNA repair
genes [32]. Recent research also suggests that this might be mediated
by SUMOylation, a process that plays a part in modulating the stability
of the FOXM1 protein [75]. The downregulation of FOXM1 expression
through transcriptional and post-transcriptional mechanisms in re-
sponse to genotoxic stress is critical for the DNA damage signals to
execute the cell cycle checkpoints at G1/S, S, G2/M and M phases. This
is mediated through the downregulation of cell cycle regulatory genes,
such as CDC25B, PLK1, Aurora B kinase, Cyclin B1, PLK1, MYC, BUB1B
and CENPF, which are under transcriptional control of FOXM1 [2]. Fur-
thermore, there is also evidence that FOXM1 cooperates with other
cell cycle gene regulators, such as B-myb and E2F, to exert wider and
more comprehensive cell cycle control [76–79]. In concordance, unreg-
ulated FOXM1expression leads to a loss inDNAdamage cell cycle check-
point control [76–79]. FOXM1 also contributes to modulating the DNA
damage-induced apoptosis and senescence. It is thought that this is
achieved by directly controlling the transcriptional activity of anti-
apoptotic and anti-senescence genes, including Bcl-2, Survivin (BIRC5),
andBmi-1, respectively [77,80,81]. So, in summary, theseﬁndings reveal
that FOXM1 impacts multiple nodes in the DNA damage checkpoint sig-
nalling network. Given the prominent role played by FOXM1 in DNA
damage checkpoint control, it is likely that in response to DNA damage
FOXM1holds the balance between repair and cell termination by senes-
cence or death.
6. Conclusion and future perspectives
Accumulating evidence has clearly pointed to the fundamental role
that FOXM1 plays in many aspects of DNA damage response. FOXM1
drives the transcription of genes encoding DNA damage sensors, media-
tors, signal transducers and effectors. Individuals with impaired DDR are
prone to developing cancer because of ineffective or inefﬁcient DNA
repair. Consequently, this results in the accumulation of DNA lesions
and oncogenic mutations. An ineffective DDR will also result in the fail-
ure to generate immunoglobulin and T-cell receptor (TCR) diversity in B
and T lymphocytes, which is essential for the recognition of pathogens
and antigens. Similarly, an inadequate DDR in neurons will lead to the
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disorders, including ataxias, Alzheimer's, Huntington's and Parkinson's
diseases. As a consequence, diminished FOXM1 activity can be involved
in the pathogenesis of cancer and other DDR-related degenerative dis-
eases, such as immune deﬁciencies and neurodegenerative disorders. In
these circumstances where FOXM1 activity and DDR are low, it may be
beneﬁcial to induce FOXM1 activity to restore normal DDR. The central
role played by FOXM1 in DNA damage response also renders it a crucial
modulator of genotoxic agent resistance. FOXM1 is a promising target
for therapeutic intervention to override resistance to genotoxic cancer
agents, such as anthracyclines, platinum compounds and ionizing radi-
ation. The thiazole antibiotics thiostrepton and Siomycin A are able to
downregulate the mRNA and protein levels of FOXM1 and so repress
transcriptional activity and induces cell death [82,83]. The fact that
this effect is only seen in cancer cells, but not in non-malignant cells, in-
dicates that cancer cells are addicted to FOXM1 overexpression [82,83].
Furthermore, breast cancer cells treated with thiostrepton also become
less migratory and invasive [82]. The exactmechanism of action of both
thiostrepton and Siomycin A is unclear, but could be related to their
ability to bind to the FKH DNA-binding domain of FOXM1, thereby
preventing FOXM1 from binding to its target genes [84]. However,
targeting FOXM1 can be a double-edged sword. On the one hand, indi-
vidualswith impairedDDR are predisposed to cancer andother diseases
because of ineffective DNA repair. On the other hand, an enhanced DDR
can confer resistance to genotoxic agents. Concordantly, it has been
demonstrated that glioma cancer stem cells acquire resistance to radio-
therapy through over-activation of the DNA damage checkpoint and
repair response [85]. Nevertheless, an elucidation of the FOXM1 gene
expression network will help to unveil the basis of cellular senescence
as well as genotoxic drug resistance. This will in turn help us to devise
better strategies for targeting FOXM1. The drug resistant FOXM1 gene
expression network in cancer can be employed as an effective drug
discovery platform to identify agents targeting DNA repair pathways
as potential anticancer agents aswell as chemo/radiotherapy sensitizers.
The FOXM1 gene signature can also be used collectively as reliable
screening, diagnostic and prognostic biomarkers for early detection of
new or recurrent cancer and for predicting and monitoring genotoxic
agent response.References
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